Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. - Wikidata - wikimedia - TriplyDB

Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.

Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.

http://www.wikidata.org/entity/Q42646492

about

Antiplatelet resistance in stroke Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update Factors affecting carisoprodol metabolism in pain patients using urinary excretion data.Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent.Clopidogrel and proton pump inhibitors: a new drug interaction?The potential interaction between clopidogrel and proton pump inhibitors: a systematic review.Novel antiplatelet agents in the prevention of cardiovascular complications--focus on ticagrelor.Antiplatelet drug interactions with proton pump inhibitors Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes A population-based study of the drug interaction between proton pump inhibitors and clopidogrel Drug-drug interaction between clopidogrel and the proton pump inhibitors.Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors.Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study.Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study.Clopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution?Antiplatelet therapy in acute coronary syndromes: current agents and impact on patient outcomes.Antiplatelet and antithrombin strategies in acute coronary syndrome: state-of-the-art review.Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan.Antiplatelet agents and proton pump inhibitors - personalizing treatment.Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome.Non-Carriers of Reduced-Function CYP2C19 Alleles are Most Susceptible to Impairment of the Anti-Platelet Effect of Clopidogrel by Proton-Pump Inhibitors: A Pilot Study.Impact of concomitant use of proton pump inhibitors and clopidogrel or ticagrelor on clinical outcomes in patients with acute coronary syndrome CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors Pharmacogenetic testing: Current Evidence of Clinical Utility.Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.P2Y12 inhibitors in cardiovascular disease: focus on prasugrel.Drug-drug interactions and their predictors: Results from Indian elderly inpatients.Increased risk for developing major adverse cardiovascular events in stented Chinese patients treated with dual antiplatelet therapy after concomitant use of the proton pump inhibitor Recent developments in clopidogrel pharmacology and their relation to clinical outcomes.P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use.Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.Proton pump inhibitor and clopidogrel interaction: fact or fiction?Prasugrel: a critical comparison with clopidogrel.Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.Drug interaction between clopidogrel and proton pump inhibitors.

P2860

Q22305927-EB9940B0-8904-4695-BE79-BF7A0117B8DC Q24633087-540CB95F-1338-4A50-A965-2C3C6FB3E7AD Q26852535-C7B4BD02-E95F-4B07-97C7-F2C625E53D73 Q26998331-302DE7A2-4317-4B6F-AEFD-BE08BABEF338 Q27022254-6D769BC7-8914-4802-ABFE-FA00FDA5D3B5 Q30746761-0D85B8D6-A0C8-49C6-A359-4B62B51B557A Q33561577-A1D029FD-D4EC-4967-BAB7-DE10B3B15F3B Q33705305-3113B330-B876-4A05-8D83-F7E917E16115 Q33763929-92DD9BC1-30CB-4F3F-A329-0BA61F4AF8DC Q33902628-462B7A62-B70C-446C-9570-F4C7AFAEE03E Q33948811-FD3698F9-AFA9-471F-A076-CE051F398D5F Q33949498-6ED63956-414C-42FB-86A0-54D7302DA93C Q34174915-E89A5E2D-BFF3-4B43-A215-B947198660D7 Q34603772-DCE852A7-D27E-4B7C-ABBA-6D434805585E Q34983154-462591E6-B4B7-4072-B6F7-A0D48F86CFD5 Q35126153-6411DA6C-B5E9-4401-97A9-BDD1BC26F3E6 Q35204942-B2BA7496-F1A8-4164-948E-E4D0FF667723 Q35222839-882A01D5-AB83-4822-88DB-CA0563F780F5 Q35959258-E5FD39A9-5805-4C3D-BCC6-092EC6852556 Q36160606-29A96B68-507B-408C-8C14-0A1CA760A14D Q36302146-49ABEFFE-7874-41C7-BCF9-123D19FA8852 Q36390258-E261CFAE-D43B-44B3-8323-8E3175CF89F8 Q36441481-D4ECA0F4-8F43-45DC-AFCE-1CCA2E662F33 Q36493369-8BEB8D1D-1D7B-4B1B-86C2-8AEA78984FC5 Q36754362-939BA5CE-3F13-4FF0-B19C-AB78FAEE4589 Q36784692-D301876A-6D02-461B-83FD-6672BF0A6EDA Q37140633-CFF75479-0F15-4ACA-9B8B-410E4DBCD0C0 Q37151528-3598A933-FCBE-43BA-B780-B7CFF1A734EE Q37259929-81A29B17-B975-4D33-9A90-2DF9FA9463BC Q37339517-E4709C5B-17DB-4AD4-B00F-A434E94408CC Q37407206-0C72AE73-2067-438E-913B-A0B06A8A28F5 Q37452994-F5EF6E7B-7C97-4677-BF4C-40CD30B50F5A Q37540088-3E818733-9C32-4019-ACF8-7968BDCE7F38 Q37562606-20AF66C0-1F81-4AE7-AB27-4F4A8AF8F9B3 Q37627874-37890F70-2CA4-481B-A375-8ECB0049A548 Q37629641-CA4C3260-3BA3-4A64-93C7-B77B4914147F Q37630911-92B520CA-A35B-4B0F-8452-911D096422C5 Q37641320-57982CEF-FDD4-444B-AECF-0790AA907A0E Q37641606-27484591-9C26-429D-B37F-1CF83E55AF60 Q37697780-8C207B61-A0C5-4764-BA93-3E4EB0C3E78F

P2860

Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.

http://www.wikidata.org/entity/Q42646492

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Effects of the proton pump inh ...... of prasugrel and clopidogrel.

@en

Effects of the proton pump inh ...... of prasugrel and clopidogrel.

@nl

type

label

Effects of the proton pump inh ...... of prasugrel and clopidogrel.

@en

Effects of the proton pump inh ...... of prasugrel and clopidogrel.

@nl

prefLabel

Effects of the proton pump inh ...... of prasugrel and clopidogrel.

@en

Effects of the proton pump inh ...... of prasugrel and clopidogrel.

@nl

P1433

Q42646492-FF4C29FC-F225-4B85-B280-BE354B413245

P1476

Q42646492-89839251-F82A-4DD4-A18D-39D4A2E58E08

P2093

Q42646492-0144E59A-C386-4C56-AB84-516B3773474B

Q42646492-0D8EB028-1A35-45B3-BA31-6F2FDCDC446B

Q42646492-1A4AA015-5170-4980-BC7F-87116D91A302

Q42646492-3B921CF7-7CBE-4A9D-8A35-3A6633B10F9E

Q42646492-48A20397-7B56-488F-9812-E1E29803864C

Q42646492-715F97BA-7391-4577-B32A-2CAE4D5FDE6C

Q42646492-B6FE0252-DFCD-4623-8E8F-FF2827C762A3

P2860

Q42646492-09CB7B60-0947-4A9F-A79B-DBA3108CE57A

Q42646492-62AA24B4-4D97-40F3-BCD7-0DCA20613B65

Q42646492-68D8B1A6-BA7B-4644-8BF0-5EC996E3FE7E

Q42646492-79B9C4C4-5FF8-4555-AF8C-418465EEFA3B

Q42646492-83126B87-10E8-4EC2-9049-01AEACD7E258

Q42646492-8F808F79-10DC-4085-84F0-581542B7DCAA

Q42646492-948A478F-1A40-4132-9EB3-D7E0C9020568

Q42646492-9FBA9185-AD0F-4EDD-B839-0EE05B57032E

Q42646492-A6CAF184-3936-4638-8640-CFBF81238174

Q42646492-EAEDA69C-9EC2-4018-9CAC-3B25EFEA7F0E

P304

Q42646492-188D5B20-30E0-4E71-A6AA-E6801843E750

P31

Q42646492-17ECD964-92CC-4EBE-86AC-F27B404BBE81

P356

Q42646492-3F45640B-8151-41DB-B74D-EF15C128DA85

P433

Q42646492-9C87F7D0-800D-4F5B-89F2-8A89AF0AC17B

P478

Q42646492-4ED0DE59-A19D-4AAC-94E3-AB0EC0EAAD5E

P50

Q42646492-07E549B6-E607-4969-9FBC-4CD289F941C7

P577

Q42646492-F8A1A22C-5548-42D2-A9FA-8D6CB3BD1C6E

P698

Q42646492-CF48C72D-67D0-48AF-A85E-D0020ECD4066

P921

Q42646492-4F3807F4-46CD-4A87-9D88-41EC7E416D6E

P356

0091270008315310

P1433

The Journal of Clinical Pharmacology

P1476

Effects of the proton pump inh ...... of prasugrel and clopidogrel.

@en

P2093

Daniel E Salazar

http://www.w3.org/2001/XMLSchema#string

David S Small

http://www.w3.org/2001/XMLSchema#string

Govinda J Weerakkody

http://www.w3.org/2001/XMLSchema#string

John T Brandt

http://www.w3.org/2001/XMLSchema#string

Kenneth J Winters

http://www.w3.org/2001/XMLSchema#string

Nagy A Farid

http://www.w3.org/2001/XMLSchema#string

Ying G Li

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial

Regulation of platelet functions by P2 receptors

Platelets in atherothrombosis.

Atherothrombosis and high-risk plaque: part I: evolving concepts.

Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders.

The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.

Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450.

The disposition of prasugrel, a novel thienopyridine, in humans.

P304

475-484

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0091270008315310

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P50

Christopher D Payne

P577

2008-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18303127

http://www.w3.org/2001/XMLSchema#string

P921